-
FDA approves 4th indication for BMS cancer drug
The FDA has granted accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T-cell therapy indicated for types of lymphoma and leukemia. -
Walgreens to sell generic naloxone
Walgreens will sell a low-cost, over-the-counter version of the opioid overdose antidote naloxone, the company said May 15. -
Scope of practice expands for Tennessee pharmacists
In early May, Tennessee Gov. Bill Lee signed a bill into law that expands pharmacists' scope of practice. -
Meet the Mangans: 2 brothers, hospital pharmacy leaders
Jim and David Mangan are two years apart in age, work about two hours from each other, and lead pharmacy operations at two different health systems in Massachusetts. -
ASHP Foundation names CEO
On June 4, Kelly McCormick-Sullivan will assume leadership of the American Society of Health-System Pharmacists' philanthropic organization. -
8 tips to enhance hospital specialty pharmacies, per McKesson
As hospitals and health systems increase investments in the specialty pharmacy industry, leaders should be nimble in their payer and drugmaker relationships, according to McKesson. -
Merck halts research on combo drug for skin cancer
Merck will stop testing an experimental combination treatment for skin cancer patients in a late-stage study, the drugmaker said May 13. -
The future chief pharmacy officer
With fewer people applying for pharmacy degree programs and residencies, it's vital for health system leaders to foster the next generation of chief pharmacy officers, executives told Becker's. -
BMS cancer drug misses goal in phase 3 trial
A phase 3 trial failed to find progression-free survival among lung cancer patients, Bristol Myers Squibb said May 10. -
Pharmacy leaders talk drug shortages: 4 insights on managing supply + patient impact
As drug shortages continue to affect day-to-day pharmacy operations and patient care, pharmacy leaders are turning to several strategies to help manage supply and mitigate impacts. -
Gene therapy candidate restores vision in some patients
In a small trial of 14 patients, a CRISPR gene editing therapy improved vision among 11 participants, according to research led by a Mass General Brigham clinician. -
FDA to consider MDMA as treatment for PTSD
An FDA panel of independent advisers is set to consider the first potential new post-traumatic stress disorder treatment in 25 years — MDMA — NBC News reported May 7. -
Child dies in gene therapy trial; Pfizer pauses study
A boy has died in Pfizer's phase 2 study of its gene therapy candidate for Duchenne muscular dystrophy, a rare genetic disorder that primarily affects boys, according to a patient advocacy group. -
Mark Cuban's drug company teams up with platform to bring patients pricing info
Patients of health systems that partner with RxLink will now receive pricing information on prescription medications offered through Mark Cuban's Cost Plus Drugs Co. -
Pharmacists now in AFib conversations: American Heart Association
Pharmacists are not often consulted in decision-making conversations about atrial fibrillation patients, the American Heart Association said, so the organization is working to engage pharmacists in AFib care. -
City of Hope, BD create exclusive pharmacy residency program
Duarte, Calif.-based City of Hope is collaborating with medical technology company Becton Dickinson to launch a new pharmacist residency program. -
Pfizer names chief strategy, innovation officer
On May 6, Pfizer appointed a former Citigroup executive as its chief strategy and innovation officer, executive vice president. -
Bill proposes paying hospitals for maintaining drug stockpiles
Following an HHS proposal, a Senate committee penned a bill to incentivize hospitals and other healthcare supply chain stakeholders for their drug shortage mitigation strategies, including stockpiles. -
Where hospital pharmacists are most in demand
In anticipation of a national shortage of hospital pharmacists, job postings increased by more than 12% in the first three months of 2024 compared to the first quarter of 2023. -
Walgreens, drugmaker team up to increase clinical trial diversity
Select Walgreens pharmacies will host Boehringer Ingelheim's clinical trials, with a focus on recruiting people who are obese, overweight or have Type 2 diabetes, Walgreens said May 2.
Page 1 of 50